TCT 2026: Edwards Pushes TAVR Into Moderate Aortic Stenosis; Medtronic Touts Renal Denervation Data
Edwards touted PROGRESS data showing SAPIEN 3 TAVR cut heart failure events in moderate AS, while EARLY TAVR economics showed cost parity. Medtronic reported significant six-month BP reductions for Symplicity Spyral in SPYRAL AFFIRM.
Medtech Insight - November 4, 2026

Madrigal Faces Whistleblower Lawsuit From Former Clinical Development Head
Former Madrigal exec Michael Charlton has filed suit against the firm alleging that he was forced out after raising concerns about potential drug-related liver damage in resmetirom studies.
Scrip - November 4, 2026

Boehringer Looks To China-Based SBP For Preclinical ADCs And TCEs
Deal Snapshot: Boehringer Ingelheim is looking to enhance its pipeline in modalities such as antibody-drug conjugates and T-cell engagers for challenging cancers, while also increasing external innovation in China.
Scrip - November 4, 2026

Servier’s Edgewise Deal Loses Luster As Sevasemten Fails In Becker MD Trial
The pivotal Phase II GRAND CANYON study of the drug, which was part of a June asset purchase from Edgewise worth up to $2.65bn in upfront and milestone payments, missed the primary endpoint.
Scrip - November 4, 2026

What’s Next For AbbVie In Immunology? Combinations, Orals And CAR-T
AbbVie VP-global head of immunology clinical development Kori Wallace talked to Scrip about what could be the company’s next Skyrizi or Rinvoq.
Scrip - November 4, 2026

FDA Cites Next Medical For Contamination Controls And Unapproved Ultrasound Gel Changes
The FDA issued a warning letter to Next Medical Products Company, citing inadequate contamination controls, failures to validate changes to its ultrasound gel formulation, and failure to report a correction involving contaminated products, and failed to obtain a new 510(k) for a reformulated gel.
Medtech Insight - November 4, 2026

US Employers Are Pushing Back On Obesity Drug Costs, Warns Novo
The new Medicare Bridge program has boosted obesity drug sales in the US, but insurance programs are pushing back as more and more individuals request the treatments.
Scrip - November 4, 2026

Pricing, Promotions And Competition For Distribution ‘Intense’ In US Multivitamins, Says Bayer
Competitive pressure is hitting Bayer’s Nutritionals business, with US multivitamins especially tough, the company told HBW Insight. Adjusted Nutritionals sales fell 3.4% in Q3, contributing to flat Consumer Health revenues. Bayer expects full-year growth in the lower half of its 0% to 4% guidance.
HBW Insight - November 4, 2026

Teva Builds On Samsung Bioepis Alliance With Another Two Products As Biosimilars Exceed Expectations
As Teva announced a significant expansion of its biosimilars alliance with Samsung Bioepis, the firm also reported that it was on track to hit its $800m biosimilars sales target for 2027 a year early, helping to partly offset a generics slide due to lower US lenalidomide turnover.
Generics Bulletin - November 4, 2026

FDA Tentative Approval Clears Path For Dr Reddy’s Launch Of Generic Lenacapavir In 120 Countries
With the FDA’s tentative approval now secured, first supplies of Dr Reddy’s generic lenacapavir long-acting injection for HIV prevention are expected to reach LMICs before the end of 2026, while broader rollout is expected next year.
Generics Bulletin - November 4, 2026

Ultragenyx’s Axe Spares Brittle Bone Drug Setrusumab, For Now
Ultragenyx will cut about a fifth of its staff and drop its Wilson disease gene therapy to reach profitability in 2027 as it launches two new gene therapies.
Scrip - November 4, 2026

Nxera Banks $100m As AbbVie Bags IBD Candidate
Deal Snapshot: The US giant has linked up again with the Japanese drugmaker, this time to license an early-stage drug for inflammatory bowel disease.
Scrip - November 4, 2026

Philips’s Diagnosis & Treatment Orders Jump Close To 20%, But Ultrasound Delays Keep Sales Flat
Diagnosis & Treatment orders rose close to 20% as Philips’s imaging rebuild gained traction, but ultrasound shipment delays and weaker China sales left segment revenue flat.
Medtech Insight - November 4, 2026

Booming Wegovy Pill Sales Offset Novo’s Decline
Novo has upgraded its full-year forecast thanks to the huge success of the Wegovy pill, but analysts want to see more action to boost its long-term growth.
Scrip - November 4, 2026

AbbVie’s Oxford R&D Expansion Is Welcome News For UK
The US-headquartered firm is growing its research base in Oxford, and the new investment could help the UK move on from last year’s row with big pharma about medicines pricing and access.
Scrip - November 4, 2026

BioNTech Bets On Pumitamig Success As CEO Transition Inches Closer
BioNTech is betting on its bispecific candidate pumitamig and says moving autogene cevumeran to a royalty-based arrangement gives it more room to fund other late-stage programs as it prepares for a new CEO by February 2027.
Scrip - November 4, 2026

Thai Hospital Group Bets On Local CAR-T Manufacturing
Major private Thai hospital group acquires domestic CAR-T biotech with a view to moving into lower-cost advanced medical therapies, in line with national strategy.
Scrip - November 4, 2026

Herbalife Looks To Drive Growth By Making Internal, Vertical Use Of Nutrition Club Strategy
Direct seller notes strategy with Q3 results, including net sales growing 6% to $1.35bn driven primarily on volume. Other priorities are digital platform offering distributors’ best apps and expanding into entrepreneur and consumer segments with Bioniq brand.
HBW Insight - November 4, 2026

Chinese First-In-Class Assets Scoop New VC/PE Funding
In October, Burgeon Therapeutics and Groovy Medicine were among the China ventures closing new early funding rounds to finance the clinical development of first-in-class molecules, in atopic dermatitis and oncology, respectively. BioGeometry, Reju and Allygen also had sizable new financings.
Scrip - November 4, 2026

UK Campaign Targets Counterfeit Beauty After Tests Find Mercury, Lead
The UK’s Trading Standards office found that four in 10 counterfeit cosmetics products tested positive for potentially harmful substances.
HBW Insight - November 4, 2026

TCT 2026: Abbott’s Amulet 360 Hits 96.3% Complete LAA Closure at One Year in Pivotal VERITAS Study
Abbott reported positive one-year results from the VERITAS study of its Amulet 360 left atrial appendage (LAA) closure device at TCT 2026. Complete closure was seen in 96.3% of patients, with a 1.8% rate of ischemic stroke or systemic embolism. The device has a CE Mark and FDA approval is expected.
Medtech Insight - November 4, 2026

Amgen Sees Big Sales Growth But Multiple Products Face Threats
Although Amgen’s revenue rose by more than 8% in the third quarter, some blockbusters are losing ground; drug candidates with recent positive late-stage readouts could help fill future gaps.
Scrip - November 4, 2026